Is investment in the microbiome having a moment?
(ALEX HOGAN/STAT)
It sure looks that way. Companies trying to turn microbes into drugs are gearing up to roll out the kind of data that interests investors. And, for the first time, the microbiome field now has a dedicated investor analyst.
As STAT's Kate Sheridan reports, it hasn't always been this way. In 2016, a high-profile clinical trial failure contributed to a chilling of investor excitement. But these days, microbiome science watchers are hopeful that the right factors are finally coming together.
“I don’t think the breadth of opportunity has been appreciated yet,” said Taylor Feehley, the Chardan analyst covering the space.
Read more.
As STAT's Kate Sheridan reports, it hasn't always been this way. In 2016, a high-profile clinical trial failure contributed to a chilling of investor excitement. But these days, microbiome science watchers are hopeful that the right factors are finally coming together.
“I don’t think the breadth of opportunity has been appreciated yet,” said Taylor Feehley, the Chardan analyst covering the space.
Read more.
No hay comentarios:
Publicar un comentario